Chemical and biological aspects of sparsomycin, an antibiotic from Streptomyces. 1986

H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz

UI MeSH Term Description Entries
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D013033 Sparsomycin An antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems.

Related Publications

H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
November 1994, The Journal of antibiotics,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
September 2002, Antimicrobial agents and chemotherapy,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
March 1948, Journal of the American Chemical Society,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
February 1947, Journal of the American Chemical Society,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
January 1990, The Journal of antibiotics,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
December 2017, Journal of global antimicrobial resistance,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
October 1971, The Journal of antibiotics,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
November 1983, Journal of medicinal chemistry,
H C Ottenheijm, and L A van den Broek, and J P Ballesta, and Z Zylicz
February 1966, Hindustan antibiotics bulletin,
Copied contents to your clipboard!